Our goal: Stimulate innovative collaborations across all sectors - academia, government, industry, investors, and nonprofits - to speed up the time it takes to get new therapies from the lab to patients.
P4C Innovator Presentations focus on cross-sector collaboration
FasterCures has announced the innovative, cross-sector collaborations that will present at this year’s Partnering for Cures, to be held Nov. 3-5 in New York. Presentations will focus on a range of issues, including Aeras’ Business Case for Investment in TB Vaccine R&D, Alzheimer’s Drug Discovery Foundation’s ACCESS Program, Carnegie Mellon University and Allegheny Health Network’s Disruptive Health Technology Institute, and the Neurological Clinical Research Institute’s Pooled Resource Open-Access ALS Clinical Trials Platform.
- Have you registered for P4C yet? Be a part of medical research’s most forward-thinking event.
Our goal: Improve research processes and develop policies that will better support efficient development and approval of new therapies.
Value and Reimbursement Workshop recommendations spell new challenges for stakeholders
At a workshop convened by FasterCures and the Cystic Fibrosis Foundation, a candid discussion focused on defining "value" in reimbursement decisions for lifesaving therapies. More than 50 leaders from across the healthcare and cure enterprises grappled with issues ranging from the evidentiary needs of payers to methods used to capture patient preferences – all toward the goal of protecting innovation in therapy development. A number of recommendations emerged toward a definition of how value is determined and how it translates into reimbursement decisions.
Anderson speaks about adjusting to a changing research environment
At the Association of Independent Research Institutes 52nd Annual Meeting on Sep. 9 in Washington, Margaret Anderson, executive director of FasterCures, spoke about adjusting to a changing research environment, including getting big ideas from small spaces, the venture philanthropy model, and patients as partners.
NIH director says budget cuts put breathtaking science in peril
National Institutes of Health (NIH) Director Francis Collins said continued sequestration cuts threaten U.S. leadership in research and could result in a loss of researchers, who now have a less than one in six chance of having their studies funded by the NIH. In an interview on public radio, Collins took questions from the audience, including one that FasterCures sent via Twitter about the value of public support for medical research. "Are we going to expand and flourish or are we going to see this hard-won set of progress slowed down by the fact that there's no resources there to support it?" Collins challenged the audience.
Patient communities need a framework to collect and analyze data and develop tools to capture benefit-risk information that will be helpful to FDA regulators. FasterCures aims to create this framework and tools for benefit-risk data collection for disease-specific patient organizations, FDA stakeholders, and policymakers. By broadly educating patient communities, this focused effort will connect the dots – externally and within FDA – to minimize duplication, amplify impact, and inform all parties involved.
Our goal: Facilitate greater access to and more strategic allocation of capital to support results-driven medical research.
Stevens focuses on financing R&D pipeline at Social Capital Markets Conference
On Sept. 4, Melissa Stevens, deputy executive director of FasterCures, moderated a panel at the Social Capital Markets Conference in San Francisco, “Forging a Pathway to Collaborative Finance in Medical Research.” The panel focused on how to better coordinate donations and investments in medical research in order to create fluid finance pipelines across diseases.
Our goal: Increase patient engagement in research.
Kids, DNA, and Genetic Testing
Adam Foye, a New-Jersey sixth grader, has lived much of his life with weak muscles and uncertainty. Although his symptoms match most closely with the rare muscular disorder Centronuclear Myopathy (CNM), his genes tell a different story. Last year, more than 20 teams of international researchers competed to analyze Adam’s genetic sequence in comparison with someone who does not have CNM and translate the results into easily ready and interpretable information for patients, families, and doctors. Read his Time=Lives story.
- Check out the Time=Lives site to find out what you can do to help make medical research a national priority and read additional stories about the power and promise of medical research to find cures and save lives.